Mixed dyslipidemia
Drug research and approvals for mixed dyslipidemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 14 studies of mixed dyslipidemia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 7 drug trials for it since 2013.
- Recruiting worldwide: 14
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 14 recruiting on ClinicalTrials.gov ↗- Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With…NCT07803822 · Phase 2 · Shanghai Minwei Biotechnology Co., Ltd · starts Sep 25, 2026
- A Study of SYH2070 Injection in Participants With Mixed HyperlipidemiaNCT07695597 · Phase 2 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · starts Jul 15, 2026
- Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat…NCT07614958 · Phase 3 · A. Menarini International Licensing S.A. · starts May 6, 2026
- A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary…NCT07206472 · Not reported · Daiichi Sankyo · starts Mar 3, 2026
- A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial…NCT07421297 · Phase 3 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · starts Feb 28, 2026
- Study of ARO-DIMERPA in Adult Participants With Mixed HyperlipidemiaNCT07223658 · Phase 1 / Phase 2 · Arrowhead Pharmaceuticals · starts Dec 22, 2025
- Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)NCT06770543 · Not reported · Novartis Pharmaceuticals · starts Aug 13, 2025
- A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111ANCT06932705 · Phase 1 · Addpharma Inc. · starts Apr 1, 2025
- Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed DyslipidemiaNCT06797401 · Phase 2 · Ribocure Pharmaceuticals AB · starts Jan 28, 2025
- A Study on Efficacy and Safety of HST101 in Chinese Patients with HypercholesterolemiaNCT06568471 · Phase 3 · Hasten Biopharmaceutical Co., Ltd. · starts Nov 16, 2024
Trials Authorized in Canada
Newest first; search them all in Canada trials| Mar 1, 2022 | A phase 2, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of ly3561774 in adults with mixed dyslipidemiaSOLBINSIRAN (LY3561774) | Eli Lilly | Closed |
| Sep 1, 2021 | A double-blind, placebo-controlled phase 2b study to evaluate the efficacy and safety of aro-apoc3 in adults with mixed dyslipidemiaADS-005 (ARO-APOC3) | ARROWHEAD PHARMACEUTICALS, INC. | Closed |
| Jun 1, 2016 | A double blind, randomized, placebo controlled, multicenter study to evaluate safety, tolerability, and efficacy on ldl-c of evolocumab (amg 145) in subjects…REPATHA | Amgen | Ongoing |
| Apr 29, 2016 | A double-blind, randomized, placebo-controlled, multicenter study to evaluate safety, tolerability, and efficacy of evolocumab (amg 145) on ldl-c in subjects…REPATHA | Amgen | Closed |
| Oct 10, 2014 | A 52 week, phase 3, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of pf-04950615 in…RN316 (PF-04950615) | Pfizer | Ongoing |
| May 16, 2014 | A phase 3 double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, long-term safety and tolerability of pf-04950615 in…RN316 (PF-04950615) | Pfizer | Closed |
| Apr 24, 2013 | "a multicenter, controlled, open-label extension (ole) study to assess the long-term safety and efficacy of amg 145."AMG 145 | Amgen | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA